Disc Medicine
Tracked across 3 events · 32 articles · First seen Apr 07, 2026 · Last active Jun 12, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Disc Medicine, Inc. received a Complete Response Letter from the United States — Food and Drug Administration regarding its bitopertin program, leading to a 22% stock price drop and subsequent securities claims investigation.
May 01, 2026 · 6 articles
Regulatory
Impact: Disc Medicine received a Complete Response Letter from the United States — Food and Drug Administration for its bitopertin program, leading to a significant drop in its stock price and a securities investigation.
Apr 29, 2026 · 20 articles
90
United States — Food and Drug Administration issued Complete Response Letter Disc MedicineRosen Law Firm...
88
Disc Medicine stock price fellRosen Law Firm...
75
Rosen Law Firm investigates securities claims Disc MedicineRosen Law Firm...
ERGEN INTELLIGENCE
Track Disc Medicine live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard